The US Food and Drug Administration (FDA) has approved Sequana Medical’s alfapump for the treatment of recurrent or refractory ascites due to liver cirrhosis. The agency’s greenlight makes ...

Sequana Medical NV has announced the US FDA approval of its Alfapump system for treating recurrent or refractory ascites due to liver cirrhosis. This approval marks Alfapump as the first active ...

Describes the nature of a clinical study. Types include: Observational study — observes people and measures outcomes without affecting results. Interventional study (clinical trial) — studies new ...

Sequana Medical Announces US FDA Approval of alfapump® for the Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosis The Company will be hosting a further webcast with key opinion ...

Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

Sequana Medical NV received premarket approval from the U.S. FDA for its Alfapump system to treat recurrent or refractory ascites due to liver cirrhosis. Data from the Poseidon pivotal study showed ...